Emergent BioSolutions Lands $1.25B BioThrax Contract
By Marie Powers
Tuesday, October 4, 2011
Patience paid off for Emergent BioSolutions Inc., which scored a big win on Monday by landing an award with the U.S. Centers for Disease Control and Prevention potentially worth $1.25 billion to supply the U.S. government with 44.75 million doses of BioThrax (anthrax vaccine adsorbed) over a five-year period.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.